paroxetine (Q408471)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

pharmaceutical drug

BRL-29060
(-)-(3S,4R)-4-(p-fluorophenyl)-3-{[3,4-(methylenedioxy)phenoxy]methyl}piperidine
(3S-trans)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine
(−)-(3S,4R)-4-(p-fluorophenyl)-3-{[3,4-(methylenedioxy)phenoxy]methyl}piperidine

Language	Label	Description	Also known as
English	paroxetine	pharmaceutical drug	BRL-29060 (-)-(3S,4R)-4-(p-fluorophenyl)-3-{[3,4-(methylenedioxy)phenoxy]methyl}piperidine (3S-trans)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine (−)-(3S,4R)-4-(p-fluorophenyl)-3-{[3,4-(methylenedioxy)phenoxy]methyl}piperidine

Statements

type of chemical entity

0 references

heterocyclic compound

0 references

1 reference

Paroxetine (English)

language of work or name

publication date

17 November 2015

chemical structure

Paroxetine Structural Formulae V.1.svg
483 × 444; 15 KB

0 references

329.143 dalton

1 reference

language of work or name

paroxetine (English)

19 October 2016

chemical formula

C₁₉H₂₀FNO₃

1 reference

language of work or name

paroxetine (English)

19 November 2016

canonical SMILES

C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4

1 reference

language of work or name

paroxetine (English)

19 November 2016

isomeric SMILES

C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4

1 reference

language of work or name

paroxetine (English)

19 November 2016

defined daily dose

20 milligram

route of administration

oral administration

1 reference

Anatomical Therapeutic Chemical Classification System

active ingredient in

1 reference

14 February 2018

1 reference

14 February 2018

1 reference

14 February 2018

World Health Organisation international non-proprietary name

paroxetine (English)

1 reference

language of work or name

Paroxetine (English)

19 January 2016

medical condition treated

obsessive-compulsive disorder

2 references

language of work or name

13 December 2016

Drug Indications Extracted from FAERS

2 October 2018

eating disorder

1 reference

language of work or name

13 December 2016

neurotic disorder

1 reference

language of work or name

13 December 2016

1 reference

language of work or name

13 December 2016

social anxiety disorder

1 reference

language of work or name

13 December 2016

post-traumatic stress disorder

2 references

language of work or name

13 December 2016

Drug Indications Extracted from FAERS

2 October 2018

generalized anxiety disorder

1 reference

Drug Indications Extracted from FAERS

2 October 2018

anxiety disorder

1 reference

Drug Indications Extracted from FAERS

2 October 2018

1 reference

Drug Indications Extracted from FAERS

2 October 2018

significant drug interaction

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

tranylcypromine

1 reference

High-priority drug–drug interactions for use in electronic health records

nature of statement

1 reference

Possible paroxetine-zolpidem interaction.

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

paralytic ileus

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

paralytic ileus

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

solute carrier family 6 member 4

subject has role

enzyme inhibitor

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

route of administration

oral administration

0 references

legal status (medicine)

1 reference

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

pregnancy category

Australian pregnancy category D

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category D

1 reference

imported from Wikimedia project

English Wikipedia

described at URL

https://cpe.org.uk/our-news/mhra-class-2-medicines-recall-paroxetine-40mg-film-coated-tablets-crescent-pharma-limited/

1 reference

https://cpe.org.uk/our-news/mhra-class-2-medicines-recall-paroxetine-40mg-film-coated-tablets-crescent-pharma-limited/

MHRA Class 2 Medicines Recall: Paroxetine 40mg Film Coated Tablets (Crescent Pharma Limited) - Community Pharmacy England (British English)

24 October 2024

subject has role

selective serotonin reuptake inhibitor

2 references

5 March 2018

Medical Subject Headings

MeSH descriptor ID

15 March 2018

cytochrome P-450 CYP2D6 inhibitors

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

second-generation antidepressive agents

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

PARoxetine

has characteristic

Tall Man lettering

Institute for Safe Medication Practices

1 reference

https://www.ismp.org/recommendations/tall-man-letters-list

2 September 2022

0 references

0 references

Commons category

Paroxetine

0 references

Identifiers

InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1

1 reference

language of work or name

paroxetine (English)

19 November 2016

AHOUBRCZNHFOSL-YOEHRIQHSA-N

2 references

language of work or name

paroxetine (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

2 references

Global Substance Registration System

language of work or name

paroxetine (English)

19 November 2016

CAS Common Chemistry

7 April 2021

https://commonchemistry.cas.org/detail?cas_rn=61869-08-7

AHOUBRCZNHFOSL-YOEHRIQHSA-N

1 reference

language of work or name

Paroxetine (English)

19 November 2016

2 references

language of work or name

paroxetine (English)

19 November 2016

matched by identifier from

AHOUBRCZNHFOSL-YOEHRIQHSA-N

Reaxys registry number

7467879

1 reference

language of work or name

paroxetine (English)

19 October 2016

mapping relation type

2 references

language of work or name

PAROXETINE (English)

19 November 2016

matched by identifier from

International Chemical Identifier

InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1

1 reference

language of work or name

PAROXETINE (English)

19 November 2016

2 references

based on heuristic

inferred from InChIKey

matched by identifier from

AHOUBRCZNHFOSL-YOEHRIQHSA-N

UniChem compound ID

1 reference

MassBank accession ID

0 references

MSBNK-Athens_Univ-AU152606

0 references

MSBNK-Waters-WA001105

0 references

MSBNK-Waters-WA001106

0 references

MSBNK-Waters-WA001107

0 references

MSBNK-Waters-WA001108

0 references

MSBNK-Waters-WA001109

0 references

splash10-001i-2409000000-077fb077fbf0e4210f51

0 references

splash10-0006-8900000000-0a273deac3c7836cdc76

0 references

1 reference

Hazardous Substances Data Bank

publication date

28 October 2019

PAROXETINE (English)

10 May 2021

DSSTox substance ID

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

matched by identifier from

AHOUBRCZNHFOSL-YOEHRIQHSA-N

DSSTOX compound identifier

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-piperidine (English)

CAS no.: 61869-08-7 (English)

ECHA Substance Infocard ID

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-piperidine (English)

CAS no.: 61869-08-7 (English)

1 reference

language of work or name

Paroxetine (English)

publication date

17 November 2015

Guide to Pharmacology Ligand ID

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

paroxetine (English)

19 November 2016

MeSH descriptor ID

subject named as

Paroxetine

0 references

MeSH concept ID

0 references

D03.383.621.600

0 references

1 reference

Global Substance Registration System

language of work or name

paroxetine (English)

19 November 2016

1 reference

matched by identifier from

AHOUBRCZNHFOSL-YOEHRIQHSA-N

Human Metabolome Database ID

2 references

based on heuristic

inferred from InChIKey

matched by identifier from

AHOUBRCZNHFOSL-YOEHRIQHSA-N

2 references

Global Substance Registration System

language of work or name

paroxetine (English)

19 November 2016

matched by identifier from

AHOUBRCZNHFOSL-YOEHRIQHSA-N

1 reference

matched by identifier from

AHOUBRCZNHFOSL-YOEHRIQHSA-N

MedlinePlus drug identifier

0 references

PatientsLikeMe treatment ID

0 references

1 reference

Global Substance Registration System

language of work or name

paroxetine (English)

19 November 2016

Probes And Drugs ID

0 references

1 reference

1 reference

language of work or name

paroxetine (English)

19 October 2016

1 reference

language of work or name

paroxetine (English)

19 October 2016

0 references

1 reference

Freebase Data Dumps

publication date

28 October 2013

1 reference

9 July 2020

Microsoft Academic ID

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

PDB structure ID

1 reference

Protein Data Bank

PDB structure ID

language of work or name

5I6X (English)

19 October 2016

1 reference

Protein Data Bank

PDB structure ID

language of work or name

3V5W (English)

19 October 2016

1 reference

Protein Data Bank

PDB structure ID

language of work or name

4JLT (English)

19 October 2016

1 reference

Protein Data Bank

PDB structure ID

language of work or name

4MM4 (English)

19 October 2016

1 reference

Protein Data Bank

PDB structure ID

language of work or name

4L9I (English)

19 October 2016

UK Parliament thesaurus ID

subject named as

Paroxetine

0 references

1 reference

Global Substance Registration System

language of work or name

paroxetine (English)

19 November 2016

WikiProjectMed ID

0 references

WordNet 3.1 Synset ID

03897548-n

1 reference

Sitelinks

Wikipedia(32 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(1 entry)

commonswiki Category:Paroxetine

Retrieved from "https://www.wikidata.org/w/index.php?title=Q408471&oldid=2264450863"